---
input_text: "Busulfan and subsequent malignancy: An evidence-based risk assessment.BACKGROUND:
  The incidence of secondary malignancies associated with busulfan exposure is considered
  low, but has been poorly characterized. Because this alkylating agent is increasingly
  utilized as conditioning prior to gene therapy in nonmalignant hematologic and related
  disorders, more precise characterization of busulfan's potential contribution to
  subsequent malignant risk is warranted. PROCEDURE: We conducted a literature-based
  assessment of busulfan and subsequent late effects, with emphasis on secondary malignancies,
  identifying publications via PubMed searches, and selecting those reporting at least
  3 years of follow-up. RESULTS: We identified eight pediatric and 13 adult publications
  describing long-term follow-up in 570 pediatric and 2076 adult hematopoietic cell
  transplant (HCT) recipients. Secondary malignancies were reported in 0.5% of pediatric
  HCT recipients, with no cases of myelodysplastic syndrome (MDS) or acute myelocytic
  leukemia (AML). Fatal secondary malignancies were reported in 0.8% of 1887 evaluable
  adult HCT recipients, and an overall incidence of secondary malignancies of 4.8%
  was reported in a subset of 389 evaluable adult patients. We also reviewed long-term
  results from eight publications evaluating lentiviral- and human promotor-based
  HSC-targeted gene therapy in 215 patients with nonmalignant conditions, in which
  busulfan/treosulfan monotherapy or busulfan/fludarabine was the only conditioning.
  Two malignancies were reported in patients with sickle cell disease (SCD), one of
  which was potentially busulfan-related. No additional malignancies were reported
  in 173 patients with follow-up of 5-12 years. CONCLUSION: The incidence of busulfan-related
  secondary malignancies is low, and likely to be substantially less than 1% in pediatric
  transplant recipients, especially those receiving busulfan monotherapy for nonmalignant
  conditions other than SCD."
raw_completion_output: |-
  primary_disease: Busulfan-related secondary malignancies

  medical_actions: Literature-based assessment; Conditioning prior to gene therapy; Hematopoietic cell transplant (HCT); Busulfan/treosulfan monotherapy; Busulfan/fludarabine conditioning

  symptoms: Secondary malignancies; Myelodysplastic syndrome (MDS); Acute myelocytic leukemia (AML); Fatal secondary malignancies

  chemicals: Busulfan; Treosulfan; Fludarabine

  action_annotation_relationships: Literature-based assessment PREVENTS unspecified risk IN Busulfan-related secondary malignancies; Conditioning prior to gene therapy (with Busulfan) TREATS nonmalignant hematologic disorders IN Busulfan-related secondary malignancies; Hematopoietic cell transplant (HCT) TREATS nonmalignant hematologic disorders IN Busulfan-related secondary malignancies; Busulfan/treosulfan monotherapy PREVENTS secondary malignancies IN Busulfan-related secondary malignancies; Busulfan/fludarabine conditioning PREVENTS secondary malignancies IN Busulfan-related secondary malignancies
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Busulfan/fludarabine conditioning PREVENTS secondary malignancies IN Busulfan-related secondary malignancies

  ===

extracted_object:
  primary_disease: Busulfan-related secondary malignancies
  medical_actions:
    - Literature-based assessment
    - Conditioning prior to gene therapy
    - MAXO:0000149
    - Busulfan/treosulfan monotherapy
    - Busulfan/fludarabine conditioning
  symptoms:
    - Secondary malignancies
    - HP:0002863
    - HP:0004808
    - Fatal secondary malignancies
  chemicals:
    - CHEBI:28901
    - CHEBI:82557
    - Fludarabine
  action_annotation_relationships:
    - subject: <Literature-based assessment>
      predicate: <PREVENTS>
      object: <unspecified risk>
      qualifier: <Busulfan-related secondary malignancies>
      subject_extension: <Literature-based assessment>
    - subject: Conditioning prior to gene therapy
      predicate: TREATS
      object: nonmalignant hematologic disorders
      qualifier: Busulfan-related secondary malignancies
      subject_qualifier: with Busulfan
      subject_extension: CHEBI:28901
    - subject: MAXO:0000149
      predicate: TREATS
      object: nonmalignant hematologic disorders
      qualifier: Busulfan-related secondary malignancies
    - subject: monotherapy
      predicate: PREVENTS
      object: secondary malignancies
      qualifier: Busulfan-related secondary malignancies
      subject_extension: Busulfan/treosulfan
    - subject: conditioning
      predicate: PREVENTS
      object: secondary malignancies
      qualifier: Busulfan-related secondary malignancies
      subject_extension: Busulfan/fludarabine
named_entities:
  - id: MONDO:0011382
    label: sickle cell disease
  - id: MONDO:0100096
    label: SARS-CoV-2
  - id: MONDO:0007374
    label: Sickle cell disease (SCD)
  - id: HP:0100602
    label: Preeclampsia
  - id: HP:0001511
    label: Intrauterine growth restriction
  - id: CHEBI:44423
    label: Hydroxyurea (HU)
  - id: CHEBI:35143
    label: Haemoglobin (Hb)
  - id: HP:0001622
    label: Preterm delivery
  - id: CHEBI:50858
    label: corticosteroids
  - id: HP:0032654
    label: Endothelial dysfunction
  - id: HP:0012418
    label: Hypoxia
  - id: HP:0001409
    label: Portal hypertension
  - id: MAXO:0001001
    label: Gene therapies
  - id: MAXO:0000756
    label: Transfusion
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation
  - id: MAXO:0001298
    label: therapy
  - id: MAXO:0009047
    label: Total hip replacement (THR)
  - id: CHEBI:22720
    label: Benzodiazepines
  - id: MONDO:0006079
    label: Acute chest syndrome (ACS)
  - id: CHEBI:24859
    label: Iodine
  - id: MONDO:0005632
    label: Acute chest syndrome
  - id: CHEBI:17334
    label: penicillin
  - id: MAXO:0000118
    label: immunizations
  - id: HP:0001903
    label: anemia
  - id: HP:0001297
    label: stroke
  - id: HP:0012532
    label: Chronic pain
  - id: CHEBI:3216
    label: Buprenorphine
  - id: HP:0001518
    label: Low birth weight
  - id: MAXO:0001006
    label: Full blood count
  - id: MAXO:0000825
    label: Reticulocyte count
  - id: MAXO:0000427
    label: Brain magnetic resonance imaging (MRI)
  - id: HP:0012592
    label: albuminuria
  - id: HP:0100543
    label: cognitive dysfunction
  - id: HP:0000739
    label: anxiety
  - id: HP:0010783
    label: Redness
  - id: CHEBI:33281
    label: antibiotics
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:145536
    label: Motixafortide
  - id: CHEBI:114786
    label: sodium metabisulfite
  - id: CHEBI:15365
    label: aspirin
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0012622
    label: CKD
  - id: MAXO:0000969
    label: optical coherence tomography (OCT)
  - id: HP:0000505
    label: visual impairment
  - id: CHEBI:28901
    label: busulfan
  - id: CHEBI:82557
    label: treosulfan
  - id: CHEBI:9570
    label: thiotepa
  - id: HP:0100603
    label: Hypertensive disorder of pregnancy (HDP)
  - id: CHEBI:26308
    label: unweighted polygenic risk score (PRS)
  - id: CHEBI:35480
    label: Analgesics
  - id: HP:0012213
    label: Decreased glomerular filtration rate
  - id: HP:0012398
    label: Peripheral oedema
  - id: HP:0001685
    label: Cardiac fibrosis
  - id: MONDO:0005570
    label: hematologic diseases
  - id: HP:0001871
    label: hematologic diseases
  - id: HP:0001712
    label: Left ventricular hypertrophy
  - id: HP:0007760
    label: SCD
  - id: MAXO:0000149
    label: Hematopoietic cell transplant (HCT)
  - id: MAXO:0010203
    label: Echocardiography
  - id: HP:0012531
    label: Pain
  - id: CHEBI:51371
    label: muscle relaxants
  - id: HP:0002140
    label: Arterial ischemic stroke
  - id: MONDO:0019402
    label: Thalassemia major
  - id: MAXO:0000536
    label: Chorionic villus sampling (CVS)
  - id: MONDO:0020380
    label: Sickle cell anemia (SCA)
  - id: MONDO:0005161
    label: Human papillomavirus (HPV) infection
  - id: MAXO:0000759
    label: HPV vaccination
  - id: MAXO:0000447
    label: Surgical removal
  - id: HP:0033138
    label: Right atrial thrombus
  - id: HP:0000989
    label: pruritus
  - id: MAXO:0010041
    label: skin grafting
  - id: MAXO:0000058
    label: Pharmacotherapies
  - id: HP:0001513
    label: obesity
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: HP:0002617
    label: vasculopathy
  - id: MAXO:0000068
    label: Transplantation
  - id: HP:0004870
    label: chronic hemolytic anemia
  - id: CHEBI:27690
    label: acetazolamide
  - id: CHEBI:22984
    label: Calcium
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0001175
    label: liver transplantation
  - id: HP:0000952
    label: jaundice
  - id: HP:0025637
    label: vasospasm
  - id: CHEBI:125354
    label: plerixafor
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0002492
    label: Acute kidney injury
  - id: HP:0002240
    label: Hepatomegaly
  - id: HP:0001744
    label: Splenomegaly
  - id: HP:0000790
    label: Hematuria
  - id: HP:0001919
    label: Acute kidney injury
  - id: MONDO:0006515
    label: Acute Pancreatitis
  - id: HP:0002155
    label: hypertriglyceridemia
  - id: HP:0001953
    label: diabetic ketoacidosis
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0001882
    label: leukopenia
  - id: HP:0003077
    label: hyperlipidemia
  - id: CHEBI:9168
    label: Sirolimus
  - id: HP:0001735
    label: Acute Pancreatitis
  - id: CHEBI:68554
    label: deferiprone (L1)
  - id: CHEBI:4356
    label: deferoxamine
  - id: HP:0000789
    label: Infertility
  - id: HP:0011134
    label: low-grade fever
  - id: HP:0001974
    label: leukocytosis
  - id: CHEBI:28001
    label: vancomycin
  - id: CHEBI:17833
    label: gentamycin
  - id: MAXO:0000950
    label: supportive care
  - id: MONDO:0004981
    label: Atrial Fibrillation
  - id: HP:0005110
    label: Atrial Fibrillation
  - id: MAXO:0000750
    label: Conditioning regimen
  - id: MONDO:0016820
    label: Moyamoya disease
  - id: HP:0100806
    label: Sepsis
  - id: HP:0001907
    label: Thromboembolism
  - id: HP:0003826
    label: Stillbirth
  - id: MONDO:0003664
    label: Hemolytic Anemia
  - id: MAXO:0001077
    label: Splenectomy
  - id: MAXO:0001039
    label: Cholecystectomy
  - id: HP:0001081
    label: Cholelithiasis
  - id: HP:0001878
    label: Hemolytic Anemia
  - id: MONDO:0002280
    label: Anemia
  - id: HP:0012569
    label: Delayed menarche
  - id: MAXO:0000194
    label: Opioid therapy
  - id: MONDO:0018373
    label: Avascular Necrosis (AVN) in Sickle Cell Disease (SCD)
  - id: HP:0002863
    label: Myelodysplastic syndrome (MDS)
  - id: HP:0004808
    label: Acute myelocytic leukemia (AML)
